<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115736</url>
  </required_header>
  <id_info>
    <org_study_id>INSEL-HINF-2017-1</org_study_id>
    <nct_id>NCT03115736</nct_id>
  </id_info>
  <brief_title>TAF for HIV-HBV With Renal Dysfunction</brief_title>
  <official_title>Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim at describing changes in renal glomerular and tubular function with&#xD;
      after the switch from TDF to TAF in HIV/HBV-coinfected patients with mild to moderate renal&#xD;
      dysfunction and to assess the virological efficacy of TAF on HBV infection.&#xD;
&#xD;
      The study will include HIV/HBV-coinfected participants of the Swiss HIV Cohort Study (SHCS)&#xD;
      who are under active care and have been on a stable, TDF-containing ART regimen for at least&#xD;
      6 months. Only patients with an estimated glomerular filtration rate (GFR) between 30 ml/min&#xD;
      and 90 ml/min will be included. All individuals who agree to participate will be switched&#xD;
      from a TDF-containing ART regimen to a TAF-containing triple ART regimen at week 0 and will&#xD;
      be followed for 48 weeks after the treatment change.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Tenofovir alafenamide (TAF) has been shown to cause less renal complications than tenofovir&#xD;
      disoproxil fumarate (TDF) while having the same virological efficacy against HIV and HBV&#xD;
      infections. In a recent study from the USA and Japan, over 90% of HIV/HBV-coinfected&#xD;
      individuals had a suppressed HBV viral load 48 weeks after TDF was replaced by TAF. Thus, TAF&#xD;
      might be a valuable treatment option for HIV/HBV-coinfected individuals with TDF-toxicity,&#xD;
      especially in the context of resistance to lamivudine and entecavir. However, the safety and&#xD;
      efficacy of TAF has not been evaluated to date in HIV/HBV-coinfected patients with renal&#xD;
      dysfunction.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        -  To evaluate changes in glomerular and tubular renal function after switch from TDF to&#xD;
           TAF in HIV/HBV coinfected patients with renal dysfunction&#xD;
&#xD;
        -  To assess the HBV virological efficacy of TAF in HIV/HBV coinfected patients with renal&#xD;
           dysfunction switching from TDF to TAF.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To assess the percentage of and reasons for treatment interruptions&#xD;
&#xD;
        -  To describe toxicity events including liver-related complications&#xD;
&#xD;
        -  To evaluate changes in liver fibrosis&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      In eligible patients willing to participate and who have signed an informed consent TDF will&#xD;
      be replaced by TAF on day 1 of the study.&#xD;
&#xD;
      Products:&#xD;
&#xD;
        -  Tenofovir alafenamide/emtricitabine (TAF/FTC) Dose: one tbl. once per day in addition to&#xD;
           at least one third compound OR&#xD;
&#xD;
        -  Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) Dose: one&#xD;
           tbl. once per day&#xD;
&#xD;
      Study Population: eligible patients from all 7 centers of the Swiss HIV Cohort Study will be&#xD;
      considered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">December 5, 2019</completion_date>
  <primary_completion_date type="Actual">December 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assessment of change in eGFR and tubular markers during the first year of TAF-containing ART</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBV suppression</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluation of HBV virological suppression and HBsAg loss after 12 months of TAF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment interruptions</measure>
    <time_frame>48 weeks</time_frame>
    <description>Description of the proportion of patients with treatment changes or interruptions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluation of the proportion of patients with adverse events during therapy, including grade 2 or above transaminases elevations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis change</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assessment of the proportion of patients with a change in liver fibrosis stage</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV and Hepatitis B Coinfection</condition>
  <arm_group>
    <arm_group_label>Switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen</description>
    <arm_group_label>Switch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV/HBV-coinfection&#xD;
&#xD;
          -  Suppressed HIV-viremia (&lt;200 cp/ml)&#xD;
&#xD;
          -  On TDF-containing ART since at least 6 months&#xD;
&#xD;
          -  eGFR &gt; 30 ml/min and &lt;90 ml/min&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Study drug considered by the treating physician not a valid option for the patient&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Decompensated liver cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Wandeler, MD MSc</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>Saint Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaude</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet médical Chave-Crottaz-Roggerto</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Infektiologie und Spitalhygiene, Universitätspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Infektionskrankheiten &amp; Spitalhygiene, Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Renal dysfunction</keyword>
  <keyword>tenofovir alafenamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

